V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 280009059 | 280006285 | null | 23.3 | Adjuvant (A) | 2015-06-16 | 2015-06-16 | STS Rhabdo rel BERNIE Vinor Cyclo | N | null | 280029783 | RITUXIMAB |
| 280009060 | 280006286 | 1.81 | 75.9 | Curative (C) | 2017-11-03 | 2017-11-11 | TRASTUZUMAB | N | null | 280029787 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 280009061 | 280006287 | 1.81 | null | Adjuvant (A) | 2016-07-29 | 2016-08-07 | IVADo | N | Y | 280029789 | METHOTREXATE HIGH DOSE |
| 280009062 | 280006289 | 1.8 | 76.4 | null | 2017-04-17 | 2017-04-20 | Cyclophosphamide High Dose | N | N | 280029792 | RITUXIMAB |
| 280009063 | 280006290 | 1.59 | 79.7 | Curative (C) | 2015-10-13 | 2016-08-16 | IVADo | N | null | 280029794 | CYCLOPHOSPHAMIDE + VINORELBINE |
| 280009064 | 280006291 | 1.55 | 85 | Curative (C) | 2015-02-23 | 2015-03-25 | Cisplatin + Doxorubicin | 02 | N | 280029796 | CARBOPLATIN + CETUXIMAB + FU |
| 280009065 | 280010730 | 1.9 | 51.7 | null | 2016-12-24 | 2017-01-05 | Ipilimumab | N | N | 280029797 | BLINATUMOMAB |
| 280009066 | 280006292 | 1.78 | 82.95 | Palliative (P) | 2013-06-07 | 2013-07-10 | CAPECITABINE + OXALIPLATIN | null | null | 280029801 | DACARBAZINE |
| 280009067 | 280010731 | 0 | 92.3 | null | 2013-03-22 | 2013-04-04 | Everolimus 10mg | 2 | N | 280029810 | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE |
| 280009068 | 280006293 | 1.88 | 53 | Palliative (P) | 2018-03-08 | 2018-03-12 | Vincristine (weekly) | Y | N | 280029812 | CHOP R |
| 280009069 | 280009289 | 1.78 | 71.5 | Neo-adjuvant (N) | 2017-06-23 | 2017-06-24 | Docetaxel | null | null | 280029813 | DARS TRIAL |
| 280009070 | 280009290 | 1.7 | 65.2 | Curative (C) | 2016-06-24 | 2016-06-24 | Cisplatin + Doxorubicin | N | N | 280029814 | BEVACIZUMAB + FLUOROURACIL |
| 280009071 | 280006296 | 1.76 | 78.3 | null | 2017-10-28 | 2017-10-29 | Trastuzumab Subcutaneous | N | N | 280029819 | BCG |
| 280009072 | 280006297 | 1.75 | 84.7 | Curative (C) | 2017-03-23 | 2017-03-23 | ETOPOSIDE | 02 | null | 280029826 | CAPECITABINE + CISPLATIN |
| 280009073 | 280006297 | 0 | 88 | null | 2014-05-20 | 2014-05-28 | VIA (Ifos 1.5g/m2) | 02 | N | 280029826 | CHOP R |
| 280009074 | 280006298 | null | 77.3 | Curative (C) | 2017-10-24 | 2017-11-14 | Carboplatin + Cetux + FU (Cycle 1) | N | N | 280029830 | CETUXIMAB + IRINOTECAN |
| 280009075 | 280006299 | 1.86 | 74.3 | Palliative (P) | 2014-09-09 | 2014-09-14 | EVEROLIMUS + EXEMESTANE | N | Y | 280029832 | DACTINOMYCIN + VINCRISTINE |
| 280009076 | 280006300 | 1.68 | 6.3 | Curative (C) | 2018-07-31 | 2018-08-05 | Mitomycin Intravesical | N | N | 280029843 | ETOPOSIDE |
| 280009077 | 280006300 | 1.64 | 65 | Curative (C) | 2012-11-14 | 2012-11-14 | CAPECITABINE + OXALIPLATIN | Y | N | 280029843 | CASPS TRIAL |
| 280009078 | 280010735 | 1.7 | 56.8 | null | 2014-09-16 | 2014-09-21 | EOX | null | Y | 280029847 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 280009079 | 280010735 | 1.81 | 79.75 | Palliative (P) | null | 2016-12-14 | EOX | 02 | N | 280029847 | VDC |
| 280009080 | 280006301 | null | 82.9 | Palliative (P) | 2017-09-20 | 2017-09-20 | Cetuximab + CISPLATIN + FLUOROURACIL | 2 | N | 280029852 | IVADO |
| 280009081 | 280006302 | 1.58 | 66.5 | null | 2016-10-02 | 2016-10-05 | Cyclophosphamide High Dose | 2 | N | 280029852 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL |
| 280009082 | 280006303 | 1.63 | 95.8 | Adjuvant (A) | 2017-03-31 | 2017-06-22 | Capecitabine | N | N | 280029854 | MITOMYCIN INTRAVESICULAR |
| 280009083 | 280006306 | 1.61 | null | Adjuvant (A) | null | 2017-12-18 | Capecitabine | null | null | 280029858 | CARBO + FLUOROURACIL |
| 280009084 | 280006306 | 1.61 | null | Curative (C) | 2016-03-28 | 2016-04-04 | CREATE TRIAL | null | null | 280029858 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 280009085 | 280011430 | 1.83 | 89.8 | Palliative (P) | 2016-09-24 | 2016-09-28 | BUSULFAN + MELPHALAN | null | N | 280029869 | PERTUZUMAB + TRASTUZUMAB |
| 280009086 | 280006307 | 1.54 | null | Curative (C) | 2016-01-17 | 2016-01-26 | ECX | n | N | 280029870 | CARBOPLATIN + LIPOSOMAL DOX |
| 280009087 | 280009301 | 1.76 | 81 | Curative (C) | 2015-04-02 | 2015-05-20 | IVADo | 02 | N | 280029873 | NIVOLUMAB |
| 280009088 | 280006309 | null | 79 | Curative (C) | 2019-04-02 | 2019-04-03 | Dactinomycin + Vincristine | N | N | 280029884 | BCG |
| 280009089 | 280006311 | 1.7 | 65 | Neo-adjuvant (N) | 2015-11-10 | 2015-11-10 | Ipilimumab | 02 | N | 280029894 | CYCLOPHOSPHAMIDE + VINORELBINE |
| 280009090 | 280009303 | null | 57.65 | null | 2014-09-21 | 2014-09-21 | CAPECITABINE + TEMOZOLOMIDE | N | N | 280029896 | PERTUZUMAB + TRASTUZUMAB |
| 280009091 | 280006314 | null | 66.9 | Palliative (P) | 2017-12-02 | 2017-12-02 | CAPECITABINE + CETUXIMAB + CISPLATIN | 02 | N | 280029901 | SUNITINIB |
| 280009092 | 280006315 | null | 79 | Palliative (P) | null | 2015-04-10 | CARBOPLATIN + FLUOROURACIL | 1 | null | 280029914 | IVADO |
| 280009093 | 280009305 | 1.75 | 79.5 | Palliative (P) | null | 2016-04-24 | Carboplatin + Cetux + FU (>Cycle 2) | 02 | N | 280029932 | DOCETAXEL |
| 280009094 | 280006317 | 1.57 | null | null | 2017-11-23 | 2017-11-23 | KESTREL Trial | N | null | 280029935 | VIDE |
| 280009095 | 280006317 | 1.77 | null | Curative (C) | 2018-05-25 | 2018-06-01 | Cetuximab+Irinotecan (Cyc2 onwards) | N | N | 280029935 | PEMBROLIZUMAB |
| 280009096 | 280006319 | 1.8 | 86 | Palliative (P) | 2016-01-20 | 2016-01-22 | Trastuzumab 21 day maintenance | 02 | N | 280029951 | METHOTREXATE HIGH DOSE |
| 280009097 | 280006320 | 1.6 | 90 | Palliative (P) | 2016-05-23 | 2016-05-26 | EVEROLIMUS + EXEMESTANE | N | N | 280029953 | CARBOPLATIN + CETUXIMAB |
| 280009098 | 280006320 | null | 84.7 | Adjuvant (A) | 2013-04-02 | 2013-04-02 | Carbo F | N | N | 280029953 | CVP R |
| 280009099 | 280006320 | 1.8 | 178 | Palliative (P) | 2019-04-06 | 2019-04-30 | GEDDIS TRIAL | 01 | N | 280029953 | NIVOLUMAB |
| 280009100 | 280006323 | 1.64 | 85.8 | Curative (C) | 2018-01-25 | 2018-02-12 | VIDE | null | null | 280029964 | CYCLOPHOSPHAMIDE + TOPOTECAN |
| 280009101 | 280006323 | null | null | Palliative (P) | 2016-03-27 | 2016-03-27 | Cisplatin + Fluorouracil + RT 5day | N | null | 280029964 | VINCRISTINE |
| 280009102 | 280006324 | 1.66 | 72.2 | Palliative (P) | 2017-05-08 | 2017-05-09 | Cisplatin + Fluorouracil + RT 5day | N | N | 280029967 | PAZOPANIB |
| 280009103 | 280006325 | 1.83 | 66.4 | Palliative (P) | null | 2016-05-09 | Carboplatin + Cetux + FU (Cycle 1) | null | null | 280029968 | VIDE |
| 280009104 | 280006327 | 1.67 | 80.55 | Palliative (P) | 2017-01-07 | 2017-01-15 | OCTREOTIDE | N | N | 280029973 | GEMCARBO |
| 280009105 | 280006329 | null | 98 | Palliative (P) | 2018-02-26 | 2018-04-07 | Mitomycin Intravesical | N | N | 280029973 | VIDE |
| 280009106 | 280011433 | 0 | null | null | 2014-08-27 | 2014-09-09 | Carbo F | N | N | 280029985 | GEDDIS TRIAL |
| 280009107 | 280009315 | 1.75 | 83 | Disease modification (D) | 2017-11-14 | 2017-11-26 | Etoposide + Ifosfamide + HD Mtx | N | N | 280029988 | DOXORUBICIN + GEMCITABINE |
| 280009108 | 280006331 | 1.56 | null | Palliative (P) | 2015-08-12 | 2015-09-05 | Carboplatin + Liposomal Doxorubicin | N | N | 280029988 | NIVOLUMAB |